Radiation absorbed dose from technetium-99m DTPA.
The whole-body retention of intravenously administered [99mTc]DTPA was measured by urine analysis and whole-body counting in eight normal subjects. On average, the elimination of [99mTc]DTPA was faster in these subjects than in 11 patients under study for hypertension whose whole-body retention data were used in MIRD Dose Estimate Report No. 12. The average residence time for [99mTc]DTPA in total body, less bladder contents, was only 65% of the MIRD value. However, despite this difference, the dosimetry is similar in both cases largely owing to the influence of radioactivity in bladder contents. Approximately 2-3% of the administered radioactivity was retained in the body for a time that was long relative to the physical half-life of 99mTc, and probably reflects a small amount of protein binding of the DTPA preparation.
D000328:Adult; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008297:Male; D008433:Mathematics; D008875:Middle Aged; D004369:Pentetic Acid / Q000652:urine; D011829:Radiation Dosage; D013667:Technetium / Q000652:urine; D016284:Technetium Tc 99m Pentetate; D001743:Urinary Bladder / Q000378:metabolism; D014554:Urination; D014915:Whole-Body Counting
D013667:Technetium; D004369:Pentetic Acid; D016284:Technetium Tc 99m Pentetate